Worldwide study aims to unlock secrets of rare lung disease
NCT ID NCT04602481
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tracks people with primary ciliary dyskinesia (PCD) worldwide to understand their symptoms, treatments, and daily life. Participants fill out questionnaires when they join and once a year after that. The goal is to gather real-world data to improve health and quality of life for people with PCD.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could provide a clearer picture of how PCD affects people over time, helping doctors and researchers improve care and quality of life.
- What could go wrong
- This is an observational study, not a treatment trial. It relies on self-reported data, which may not be complete or accurate, and results may take years to emerge.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,500 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2020
- Expected to finish
-
May 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study includes all persons with primary ciliary dyskinesia who can be contacted via patient organisation networks worldwide.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * People of any age with reported suspected or confirmed Primary Ciliary Dyskinesia who gave consent to participate in the study Exclusion Criteria: * People who report not to have suspected or confirmed Primary Ciliary Dyskinesia
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Primary ciliary dyskinesia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Institute of Social and Preventive Medicine (ISPM), University of Bern
RECRUITINGBern, 3012, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could exercise be a new way to clear lungs in PCD?
- Can better testing unlock the secrets of a rare lung disease?
- Tiny hairs in fallopian tubes may hold key to ectopic pregnancy
- Could a simple saltwater mist make breathing easier for lung patients?
- Rare lung disease study aims to uncover key health markers
- 300-Patient study aims to unlock secrets of rare lung disease